https://www.sinchew.com.my/content/content_2370608.html?fbclid=IwAR1sw8SxV76prCGEiUGn0mObOXAkQt5I5pOn6uwTmaNBqvp4Kdncj9GBFXE

It is dangerous to enter now.

It may limit up tomorrow.

Rush up before the market closes.

limit up is coming.

It should be good.

5172 KSTAR K-STAR SPORTS LIMITED
Additional Listing Announcement /Subdivision of Shares

1. Details of corporate proposalWhether the corporate proposal involves the issuance of new type and new classof securities? NTypes of corporate proposal : Exercise of WarrantsDetails of corporate proposal : Conversion of Warrants 2018/2021 to OrdinarySharesNo. of shares issued under this corporate proposal : 1,207,600Issue price per share ($$) : 0.0800Par Value ($$) (if applicable) : 0.000Latest issued share capital after the above corporate proposalIn the followingUnits : 476,435,900Issued Share Capital ($$) : Singapore Dollar (SGD) 22,628,921.010Listing Date : 04/11/2020Remarks:You are advised to read the entire contents of the announcement or attachment.To read the entire contents of the announcement or attachment, please accessthe Bursa website at http://www.bursamalaysia.com


03/11/2020 02:52 PM

应变破疫境 宝翔强势崛起
Sinchew Mon, Nov 02, 2020 07:31pm - 20 hours ago




冠病挥之不散，手套和口罩需求暴增，马股手套股猪笼入水，业绩股价都持续缔造新纪录。

就当市场认定手套股是最大赢家之际，近期却有一家低调的纺织公司发布了让市场为之一振的季度业绩；背后推手，正是该公司不久前才推出的布制抗菌口罩火速渗透市场，拿下惊人销量。

是的，本期《股海捞月》要追踪的正是强势崛起的“口罩股”——宝翔控股（PRLEXUS,8966,主板消费产品服务组）。

在纺织领域打滚了超过40年的宝翔控股，是国内最大的服装制造公司之一，长期为知名跨国服装和运动品牌代工生产高品质衣物，如耐克（NIKE）、Under Armour、ASICS、GAP等等，在国内和中国共设有3家工厂，员工数量超过3000人，每年可生产超过1500万件衣物。

为强化核心业务，两年前进一步把业务扩大至纺织厂，自行生产布料以保障原料供应和价格的稳定性，同时开拓新收入源。最新发展显示这布局极具前瞻性，宝翔在疫情期间成功杀出血路，拥有自家纺织厂正是要素之一。

营运纪录佳 业务稳定扩张

虽然管理风格低调令曝光率偏低，宝翔却是一家基本面和营运纪录都极佳的公司，除了每年赚钱，业务规模也稳定扩张，多年来的良好营运纪录显示公司拥有强大管理层，总能适时推出有效的应变策略，助公司一路乘风破浪，晋升成制衣大厂。

今年初，面对突然杀到的冠病，大家都以为制衣订单必受冲击，随时攸关存亡，但宝翔管理层很快启动应变计划，利用几十年累积的核心制衣经验和技术进军个人防护装备（PPE）市场，公司研发团队不负所托，火速研发出一款高效布制抗菌口罩“ProXmask”，并在今年中正式推出市场，结果产品一出闸便热爆市场，短短3个月竟狂收超过3000万令吉销量，打出一场堪称典范的完美翻生仗。

ProXmask销售惊人
3个月净利超越33个月净利总和

受口罩业务爆单带动，宝翔截至2020年7月30日第四季业绩强势反弹，净赚2387万6000令吉。换句话说，最新的3个月净利就已超越过去33个月辛苦累积的净利总和，非常夸张，也清楚说明了宝翔新推出的口罩有多成功。

董事部在文告中补充，口罩业务在第四季为集团贡献了33%营业额。按该季9793万营业额计算，口罩销量预计接近3300万令吉。

要知道，宝翔今年5月才推出ProXmask，推出后还需花时间宣传，向客户解释，提升市场知名度，因此能在“出道”3个月里便累积超过3000万令吉销量，确实非常惊人，而造就这记录的关键，相信在于其口罩的高效抗菌功能。

ProXmask口罩采用来自欧洲的布料抗菌技术，获澳洲彼得朵赫迪传染与免疫中心实验证实能令99.99%冠病病毒陷入不活跃状态。ProXmask也已赢得专业和官方认证，包括获新加坡Intertek实验证实能有效阻断冠病和各种流感病毒，也通过大马全国职业安全及卫生机构（NIOSH）安全认证，更获得著名柔佛新山苏丹后阿米娜医院发函肯定高品质并推荐前线人员使用。

在疫情肆虐的当儿，上述认证肯定是最有力行销语言，加上宝翔多年来建立的强大销售网，ProXmask才能在如此短时间内迅速渗透市场，把危机变商机。

业绩展望或有惊喜

宝翔不是马股中唯一试图在疫中转型的公司，今年宣布进军手套或口罩的公司不是几家，而是一堆。宝翔与其他公司的差别是，生产布制口罩并不是陌生的新生意，而是原有核心业务的延申，这让宝翔能迅速实现商业概念，而非如多数公司般摸石度河，迟迟不到岸。

鉴于宝翔的计划是进攻个人防护设施市场，而口罩只是其中一种产品而已，用于口罩的抗菌技术其实也可应用在其他布制产品上，如布制抗菌服装、布制抗菌头巾等，纺织厂甚至能生产和供应抗菌布料，令宝翔的未来充满希望。

从供应、制造至分销公司核心强项

虽然许多公司争相涌入口罩市场，但几乎都是投资在较易制造的一次性口罩，优质布制口罩门槛相对高，所以宝翔在这方面占据极佳优势，因从布料供应至最终产品制造和分销本就是公司的核心强项，而这耗时几十年所建立起的强大竞争力，其他新晋公司根本望尘莫及。

需求方面，虽然市场在疫情爆发初期集体涌向一次性口罩，但随质感和功能都更好的抗菌布制口罩问世，加上用后即弃的口罩非常不环保，近几个月来市场需求已开始转向可循环使用口罩，渗透率预计会继续明显上扬。

全球疫情如今已进入第三波感染，每日新增病例屡创新高。如此背景下，完美起跑的ProXmask形式大好，短期内大有可能越战越勇，加上其他崭新抗菌纺织产品亦可能带来积极贡献，因此上季的佳绩也许只是前奏，不排除好戏在后头。

净现金公司 财务强稳

除了未来业绩或藏有大惊喜，宝翔财务状况也非常健康。最新数据显示，该公司已重新成为净现金公司，账目也一如既往般干净，简单明了，收支管理依然严谨。实际上，宝翔多年来的财务状况都非常强稳，大多时间都处于净现金状态，且每年都会把部份盈利用于派息，资金调配得宜，管理绩效无可挑剔。

在刚过去的2020财政年，宝翔报净利1763万令吉，每股盈利10.09仙；以截至上周五的1令吉47仙股价计算，宝翔本益比大概是16倍，看似不低。不过，鉴于口罩业务迟至第四季才开始贡献，而当季每股盈利便高达13.67仙，显示宝翔的未来估值可能被严重低估。

换句话说，若末季的超强表现能在来年延续，甚至再创纪录，那宝翔目前股价就显得极度便宜，有机会继续发威，反之则可能后继无力。因此，将在今年12月公布的2021年第一季业绩，非常关键。

整体而言，鉴于疫情让个人防护深受重视，利用抗菌科技精准捕获新商机的宝翔，比起过往任何时候都更自信、更有潜能。一手包办布料生产供应和纺织品制造，配合优秀管理团队和强大销售网络，宝翔已开始谱出精彩绝伦的成功故事。

欲知后续如何，耐心等候12月的到来吧。

Go up again.

OTHERS Prolexus Berhad ("Prolexus" or "the Company") Registration with FDA
PROLEXUS BERHAD

Type Announcement
Subject OTHERS
Description
Prolexus Berhad ("Prolexus" or "the Company") Registration with FDA
The Company wishes to inform that Honsin Apparel Sdn. Bhd. (“Honsin”), a wholly-owned subsidiary of the Company, has obtained a Certificate of Registration from Registrar Corp to certify that Honsin is registered with the U.S. Food and Drug Administration (“FDA”) for face mask (except N95 respirator) for general public / healthcare personnel per Immediately in Effect Guidance (“IIE Guidance”).



The Company also wishes to inform that the registration of CE marking with the European Union is still in progress. An update of the development will be announced in due course.



This announcement is dated 02 November 2020.

Still very strong.

It will rise even higher after the rebound.

Don’t worry about it rising again at noon.

TheEdge Wed, Oct 28, 2020 07:37pm - 12 hours ago


KUALA LUMPUR (Oct 28): HeiTech Padu Bhd has been awarded a second contract by the National Registration Department (NRD) this year, with the latest one worth a higher RM50.97 million.

In a filing with Bursa Malaysia today, HeiTech Padu said the company today signed the letter of award of the Comprehensive Main Business System Application Support and Maintenance Services for the NRD.

It said the contract is for a period of 36 months commencing from Nov 1, 2020 to Oct 31, 2023.

"The contract is expected to have positive effects on future earnings and earnings per share of HeiTech. Nevertheless, the contract will have no material effect on the dividend policy, share capital and substantial shareholdings of the company for the financial year ending Dec 31, 2020," HeiTech Padu added.

Earlier in April this year, HeiTech Padu announced that it had bagged a RM19.89 million hardware and software upgrade contract from the NRD.

The two-year contract commenced on May 1.

Besides that, HeiTech Padu was also awarded a RM126.02 million maintenance and technical support services contract from the Road Transport Department of Malaysia on May 21.

The job, which involves the maintenance and technical support services for hardware and software of mainframe systems, is for 29 months — from May 1, 2020 until Sept 30, 2022.

It is also worth highlighting that HeiTech Padu is currently one of the 25 bidders for the government's National Integrated Immigration System (NIIS) project.

The Edge Malaysia weekly, in its June 22 edition, reported that HeiTech Padu was bidding for the contract with My EG Services Bhd and S5 Systems Sdn Bhd as a consortium.

Note that HeiTech Padu was the developer of the incumbent Malaysian Immigration System (myIMMS), which was first used by the government in 1993 and which the NIIS will replace.

Other companies bidding for the job included Iris Corp Bhd, Datasonic Group Bhd, Dagang NeXchange Bhd, Dataprep Holdings Bhd, Scicom (MSC) Bhd, Omesti Bhd and Kumpulan Fima Bhd, the weekly reported.

It is unclear when the contract — meant to replace the RM3.5 billion National Immigration Control System contract awarded to Prestariang Bhd — will be awarded, since the August deadline expected by the market had elapsed.

Shares in HeiTech Padu fell two sen or 1.63% today to close at RM1.21 — valuing the company at RM122.48 million.

Definitely more than 1.65.

take over is coming

NTA:RM3.55

take over is coming
KWANTAS NTA RM3.5528
1.380
+0.04 (+3%)
OTHERS KWANTAS CORPORATION BERHAD ("KWANTAS" OR "COMPANY") PROPOSED SELECTIVE CAPITAL REDUCTION AND REPAYMENT EXERCISE OF KWANTAS PURSUANT TO SECTION 116 OF THE COMPANIES ACT, 2016 ("PROPOSED SCR")
KWANTAS CORPORATION BERHAD

Type Announcement
Subject OTHERS
Description
KWANTAS CORPORATION BERHAD ("KWANTAS" OR "COMPANY") PROPOSED SELECTIVE CAPITAL REDUCTION AND REPAYMENT EXERCISE OF KWANTAS PURSUANT TO SECTION 116 OF THE COMPANIES ACT, 2016 ("PROPOSED SCR")
(Unless otherwise stated, all abbreviations used in this announcement shall have the same meanings as defined in the Company’s announcement dated 25 September 2020 in relation to the Proposed SCR) We refer to the announcements dated 26 August 2020, 28 August 2020, 2 September 2020, 25 September 2020 and 29 September 2020 in relation to the Proposed SCR. On behalf of the Board, Maybank IB wishes to announce that the Securities Commission Malaysia had, vide its letters dated 27 October 2020, notified that it has no further comments on the circular and independent advice letter in relation to the Proposed SCR. This announcement is dated 28 October 2020.




Announcement Info
Company Name KWANTAS CORPORATION BERHAD
Stock Name KWANTAS
Date Announced 28 Oct 2020
Category General Announcement for PLC
Reference Number GA1-27102020-00129

take over is coming
KWANTAS
1.380
+0.04 (+3%)
OTHERS KWANTAS CORPORATION BERHAD ("KWANTAS" OR "COMPANY") PROPOSED SELECTIVE CAPITAL REDUCTION AND REPAYMENT EXERCISE OF KWANTAS PURSUANT TO SECTION 116 OF THE COMPANIES ACT, 2016 ("PROPOSED SCR")
KWANTAS CORPORATION BERHAD

Type Announcement
Subject OTHERS
Description
KWANTAS CORPORATION BERHAD ("KWANTAS" OR "COMPANY") PROPOSED SELECTIVE CAPITAL REDUCTION AND REPAYMENT EXERCISE OF KWANTAS PURSUANT TO SECTION 116 OF THE COMPANIES ACT, 2016 ("PROPOSED SCR")
(Unless otherwise stated, all abbreviations used in this announcement shall have the same meanings as defined in the Company’s announcement dated 25 September 2020 in relation to the Proposed SCR) We refer to the announcements dated 26 August 2020, 28 August 2020, 2 September 2020, 25 September 2020 and 29 September 2020 in relation to the Proposed SCR. On behalf of the Board, Maybank IB wishes to announce that the Securities Commission Malaysia had, vide its letters dated 27 October 2020, notified that it has no further comments on the circular and independent advice letter in relation to the Proposed SCR. This announcement is dated 28 October 2020.




Announcement Info
Company Name KWANTAS CORPORATION BERHAD
Stock Name KWANTAS
Date Announced 28 Oct 2020
Category General Announcement for PLC
Reference Number GA1-27102020-00129

KWANTAS The good news is coming.
1.380
+0.04 (+3%)
OTHERS KWANTAS CORPORATION BERHAD ("KWANTAS" OR "COMPANY") PROPOSED SELECTIVE CAPITAL REDUCTION AND REPAYMENT EXERCISE OF KWANTAS PURSUANT TO SECTION 116 OF THE COMPANIES ACT, 2016 ("PROPOSED SCR")
KWANTAS CORPORATION BERHAD

Type Announcement
Subject OTHERS
Description
KWANTAS CORPORATION BERHAD ("KWANTAS" OR "COMPANY") PROPOSED SELECTIVE CAPITAL REDUCTION AND REPAYMENT EXERCISE OF KWANTAS PURSUANT TO SECTION 116 OF THE COMPANIES ACT, 2016 ("PROPOSED SCR")
(Unless otherwise stated, all abbreviations used in this announcement shall have the same meanings as defined in the Company’s announcement dated 25 September 2020 in relation to the Proposed SCR) We refer to the announcements dated 26 August 2020, 28 August 2020, 2 September 2020, 25 September 2020 and 29 September 2020 in relation to the Proposed SCR. On behalf of the Board, Maybank IB wishes to announce that the Securities Commission Malaysia had, vide its letters dated 27 October 2020, notified that it has no further comments on the circular and independent advice letter in relation to the Proposed SCR. This announcement is dated 28 October 2020.




Announcement Info
Company Name KWANTAS CORPORATION BERHAD
Stock Name KWANTAS
Date Announced 28 Oct 2020
Category General Announcement for PLC
Reference Number GA1-27102020-00129

There should be good news that has not been announced.

9.9sen cannot attract people.

The stock price will go higher when the vaccine starts to sell.

limit up is coming.

hold

https://www.enanyang.my/%E5%85%A8%E7%90%83%E5%A4%A7%E6%8A%97%E7%96%AB/%E7%89%9B%E6%B4%A5%E7%96%AB%E8%8B%97%E5%AE%9E%E9%AA%8C%E4%BC%A0%E5%A5%BD%E6%B6%88%E6%81%AF-%E9%95%BF%E8%80%85%E5%B9%B4%E8%BD%BB%E4%BA%BA%E7%8E%B0%E5%85%8D%E7%96%AB%E5%8F%8D%E5%BA%94?fbclid=IwAR1LkEnfkEkKkfUrdw__3qBPA2zFTZaAkrktBwy0r63OQJOYrnxWkIudRD8




全球大抗疫
牛津疫苗实验传好消息 长者年轻人现免疫反应
2020年10月26日
（伦敦26日讯）英国阿斯利康公司26日说，牛津大学正在开发的冠病疫苗，在年长者和年轻人身上都已产生免疫反应，而且年长者身上出现副作用的机率比较低。

英国《金融时报》引述2名熟悉相关研究结果的人士报道，由牛津大学和阿斯利康公司研发中的疫苗，在年长者群组中激发了保护抗体与T细胞。


报道指出，在年长参与者身上开展的免疫原性血液测试，与7月公布的资料相呼应。

当时资料显示，这款疫苗在年龄介于18到55岁健康成年人身上，产生“强大的免疫反应”。

长者反应原性比较低


阿斯利康公司一名发言人说：“看到年长者身上产生的免疫反应与年轻成年人类似，以及在冠病重症机率较高的年长者身上出现的反应原性比较低，都令人感到鼓舞。”

反应原性通常是指典型的疫苗副作用，例如注射部位疼痛、发红、发热等。

《金融时报》指出，相关发现的细节预期不久后将于一份临床期刊中公布。

KSTAR
0.315
(%)
MEMORANDUM OF UNDERSTANDING K-STAR SPORTS LIMITED ('K-STAR' OR THE 'COMPANY') - MEMORANDUM OF UNDERSTANDING FOR APPOINTMENT OF K-STAR OR ANY ONE OF THE SUBSIDIARIES OF K-STAR AS THE SALE AGENT FOR COVID-19 VACCINES IN MALAYSIA
K-STAR SPORTS LIMITED

Type Announcement
Subject MEMORANDUM OF UNDERSTANDING
Description
K-STAR SPORTS LIMITED ('K-STAR' OR THE 'COMPANY') - MEMORANDUM OF UNDERSTANDING FOR APPOINTMENT OF K-STAR OR ANY ONE OF THE SUBSIDIARIES OF K-STAR AS THE SALE AGENT FOR COVID-19 VACCINES IN MALAYSIA
The Board of Directors of K-Star wishes to announce that the Company has on 26 October 2020 entered into a Memorandum of Understanding ("MoU") with Kanger International Berhad ("KIB") for the appointment of K-Star or any one of the subsidiaries of K-Star as the sale agent for Covid-19 vaccines for the private clinics in Malaysia. K-Star intends to expand its business activities into the healthcare sector and the sale and marketing of Covid-19 vaccines arising herein will be undertaken by one of the subsidiaries of K-Star (to be identified in due course). Please refer to the attachment for details of the announcement. This announcement is dated 26 October 2020.



Please refer attachment below.

Attachments
K-Star Sports Limited - MoU with Kanger International Berhad - 26.10.2020.pdf
49.7 kB

KSTAR
0.315
(%)
MEMORANDUM OF UNDERSTANDING K-STAR SPORTS LIMITED ('K-STAR' OR THE 'COMPANY') - MEMORANDUM OF UNDERSTANDING FOR APPOINTMENT OF K-STAR OR ANY ONE OF THE SUBSIDIARIES OF K-STAR AS THE SALE AGENT FOR COVID-19 VACCINES IN MALAYSIA
K-STAR SPORTS LIMITED

Type Announcement
Subject MEMORANDUM OF UNDERSTANDING
Description
K-STAR SPORTS LIMITED ('K-STAR' OR THE 'COMPANY') - MEMORANDUM OF UNDERSTANDING FOR APPOINTMENT OF K-STAR OR ANY ONE OF THE SUBSIDIARIES OF K-STAR AS THE SALE AGENT FOR COVID-19 VACCINES IN MALAYSIA
The Board of Directors of K-Star wishes to announce that the Company has on 26 October 2020 entered into a Memorandum of Understanding ("MoU") with Kanger International Berhad ("KIB") for the appointment of K-Star or any one of the subsidiaries of K-Star as the sale agent for Covid-19 vaccines for the private clinics in Malaysia. K-Star intends to expand its business activities into the healthcare sector and the sale and marketing of Covid-19 vaccines arising herein will be undertaken by one of the subsidiaries of K-Star (to be identified in due course). Please refer to the attachment for details of the announcement. This announcement is dated 26 October 2020.



Please refer attachment below.

Attachments
K-Star Sports Limited - MoU with Kanger International Berhad - 26.10.2020.pdf
49.7 kB

5172 KSTAR K-STAR SPORTS LIMITED
Additional Listing Announcement /Subdivision of Shares

1. Details of corporate proposalWhether the corporate proposal involves the issuance of new type and new classof securities? NTypes of corporate proposal : Exercise of WarrantsDetails of corporate proposal : Conversion of Warrants 2018/2021 to OrdinarySharesNo. of shares issued under this corporate proposal : 1,570,000Issue price per share ($$) : 0.0800Par Value ($$) (if applicable) : 0.000Latest issued share capital after the above corporate proposalIn the followingUnits : 475,228,300Issued Share Capital ($$) : Singapore Dollar (SGD) 22,597,233.590Listing Date : 27/10/2020Remarks:You are advised to read the entire contents of the announcement or attachment.To read the entire contents of the announcement or attachment, please accessthe Bursa website at http://www.bursamalaysia.com


26/10/2020 02:34 PM

take over is coming.

Can reach 0.70 today

It will rebound tomorrow.

It has risen a lot before and now it is normal to adjust some.

It is not a problem that this counter will go to RM20 next year.

Large households will enter at any time.

There is no need to worry about the rebound sooner or later.

Collect while low.

Performance time is coming.

It may close higher this afternoon.

Bursa Malaysia Latest Dividend News

ENTITLEMENT NEWS
COMPANY NAME KARYON INDUSTRIES BERHAD
STOCK CODE/SHORT NAME KARYON/0054
ANNOUNCEMENT DATE 01 Oct 2020
SUBJECT Second Interim Dividend .7 cent
CONTENT
EX-DATE 14 Oct 2020 ENT. IN % 0.00
ENTITLEMENT DATE 15 Oct 2020 ENT. IN CENT 0.7000
PAYMENT DATE 30 Oct 2020 ENT. NUMERATOR -
TRANSFER DATE 15 Oct 2020 ENT. DENUMERATOR -

Be careful with the suite.

The shark is here again.

5073 NAIM NAIM HOLDINGS BHD
General Meetings: Outcome of Meeting

52047Indication: Notice of MeetingIndication: Outcome of MeetingDate of Meeting: 06/10/2020Time of Meeting: 10:00 AMVenue: Employee Lounge, Naim Holdings Berhad,10th Floor, Wisma Naim,2 1/2 Mile,Rock Road,93200 Kuching, Sarawak,MalaysiaOutcome of Meeting: The Board of Directors of Naim Holdings Berhad is pleasedto announce that the ordinary resolution as set down in the Notice ofExtraordinary General Meeting ("EGM") dated 21 September 2020 has been approvedby the shareholders at the EGM held earlier today. The ordinary resolutionwas voted by poll and the results of the poll were validated by ScrutineerSolutions Sdn. Bhd., the independent scrutineer appointed by the Company.Remark:You are advised to read the entire contents of the announcement or attachment.To read the entire contents of the announcement or attachment, please accessthe Bursa website at http://www.bursamalaysia.com


06/10/2020 12:32 PM

Don't worry about it rising.

Noon will be the show time.

Duopharma stock rises as EPF increases stake
TheEdge Mon, Oct 05, 2020 10:45am - 51 minutes ago


KUALA LUMPUR (Oct 5): Duopharma Biotech stock price has seen a steady rise since July amid vaccine optimism and it is expected to continue its upward momentum as the Employees Provident Fund (EPF) has increased its holdings.

An analyst said retail investors usually would mirror the movement of institutional investors which would be on a “buy low sell high” trend.

“The two top pharmaceutical companies in Malaysia, namely Pharmaniaga, which is owned by the Armed Forces Fund Board (LTAT), and Duopharma would be the biggest gainers once the COVID-19 vaccine is available.

“Hence, the prospects for ‘buy’ is maintained for the long run,” she said.

In terms of stake, Duopharma’s majority shareholder Bumiputera Investment Foundation holds 46.5 per cent, EPF (7.82 per cent) and Permodalan Nasional Bhd (4.94 per cent).

As at 10.26pm, Duopharma stock rose five sen to RM3.38 with 1.94 million shares traded.

I believe it will limit up today.

It would be great if it rose like G3.

What price is the limit up? .

will limit up again today.

Today it will be above 0.3.